• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Prazosin for Treatment of Patients with PTSD and Comorbid Alcohol Dependence.
【24h】

Prazosin for Treatment of Patients with PTSD and Comorbid Alcohol Dependence.

机译：哌唑嗪治疗创伤后应激障碍和合并酒精依赖患者。

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There is a high rate of comorbidity with alcohol dependence (AD) and post traumatic stress disorder (PTSD). The rates of TSD among individuals with AD are at least twice as high as those in the general population. In addition, alcohol dependence is the most common comorbid condition in men with PTSD. Despite this, little is known about how to best treat individuals with comorbid AD and PTSD. The use of an alpha-1 adrenergic receptor antagonist represents a novel approach to treatment that may target symptoms of both AD and PTSD. There is evidence of common neurobiological mechanisms that underlie both AD and PTSD. Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with TSD, and alcohol dependence. Objective: The objective of this study is to evaluate the efficacy of prazosis (16mg) versus placebo in reducing alcohol consumption and increasing symptoms of PTSD in patients with comorbid AD and PTSD. Methods: One hundred and twenty participants with a current diagnosis of AD and PTSD will be enrolled in a 13-week trial. They will be assigned, in a double-blind fashion, to either prazosin or placebo. findings: No fmdings are yet available for this study. Significance: This project will be the first to compare prazosin to placebo as effective treatments for reducing alcohol consumption and PTSD symptoms in patients with both AD and PTSD.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号